09:00 AM EDT, 06/24/2025 (MT Newswires) -- TuHURA Biosciences ( HURA ) said Tuesday it has launched a phase 3 study of IFx-2.0 as an adjunctive therapy to Keytruda in the first-line treatment of advanced or metastatic Merkel cell carcinoma.

The study will assess overall response rate as the primary endpoint and progression-free survival as a key secondary endpoint, the company said.

The trial launch triggered a $2.2 million funding tranche under the company's previously announced $12.5 million private placement financing, TuHURA Biosciences ( HURA ) said.